Literature DB >> 8495259

Bone metabolism in rheumatoid arthritis; relation to disease activity.

F Eggelmeijer1, S E Papapoulos, M L Westedt, H C Van Paassen, B A Dijkmans, F C Breedveld.   

Abstract

Biochemical parameters of bone metabolism were investigated in 105 ambulant, non-steroid treated patients with RA and compared with parameters of disease activity. Urinary calcium (Ca) and hydroxyproline (OHP) excretions, as parameters of bone resorption and serum alkaline phosphatase (AP), as a parameter of bone formation, were positively related to parameters of disease activity. Serum osteocalcin, another parameter of bone formation, was not related to parameters of disease activity. Patients with active disease (ESR > or = 28 mm and Ritchie articular index > or = 8) had a significant higher urinary Ca and OHP excretion (62 and 42% higher, respectively) than patients with inactive disease. Serum AP and OC were slightly higher (19 and 16%, respectively) in patients with active disease. These results suggest that in RA patients bone metabolism is related to disease activity. In active disease bone resorption seems to be increased more than bone formation, suggesting that prolonged disease activity may contribute to generalized and/or localized osteopenia.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8495259     DOI: 10.1093/rheumatology/32.5.387

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  9 in total

1.  Should we look for osteoporosis in patients with rheumatoid arthritis?

Authors:  W F Lems; B A Dijkmans
Journal:  Ann Rheum Dis       Date:  1998-06       Impact factor: 19.103

2.  Inflammatory factors in the circulation of patients with active rheumatoid arthritis stimulate osteoclastogenesis via endogenous cytokine production by osteoblasts.

Authors:  J L Pathak; N Bravenboer; P Verschueren; W F Lems; F P Luyten; J Klein-Nulend; A D Bakker
Journal:  Osteoporos Int       Date:  2014-07-16       Impact factor: 4.507

3.  Combined effects of infliximab and methotrexate on rheumatoid arthritis osteoblastic cell metabolism.

Authors:  Addolorata Corrado; Anna Neve; Arcangela Marucci; Annamaria Gaudio; Francesco Paolo Cantatore
Journal:  Clin Exp Med       Date:  2014-08-23       Impact factor: 3.984

4.  Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis.

Authors:  W F Lems; M I Gerrits; J W Jacobs; R M van Vugt; H J van Rijn; J W Bijlsma
Journal:  Ann Rheum Dis       Date:  1996-05       Impact factor: 19.103

5.  Bone turnover in non-steroid treated rheumatoid arthritis.

Authors:  J E Compston; S Vedi; P I Croucher; N J Garrahan; M M O'Sullivan
Journal:  Ann Rheum Dis       Date:  1994-03       Impact factor: 19.103

6.  Osteoporosis in rheumatoid arthritis: effect of disease activity.

Authors:  R Celiker; Y Gökçe-Kutsal; A Cindas; M Ariyürek; N Renda; Z Koray; O Basgöze
Journal:  Clin Rheumatol       Date:  1995-07       Impact factor: 2.980

7.  Infliximab prevents systemic bone loss and suppresses tendon inflammation in a collagen-induced arthritis rat model.

Authors:  Frideriki Poutoglidou; Chryssa Pourzitaki; Maria Eleni Manthou; Efthimios Samoladas; Athanasios Saitis; Foteini Malliou; Dimitrios Kouvelas
Journal:  Inflammopharmacology       Date:  2021-05-12       Impact factor: 4.473

Review 8.  Bone loss. Therapeutic approaches for preventing bone loss in inflammatory arthritis.

Authors:  Q Rehman; N E Lane
Journal:  Arthritis Res       Date:  2001-05-18

Review 9.  Bone effects of biologic drugs in rheumatoid arthritis.

Authors:  Addolorata Corrado; Anna Neve; Nicola Maruotti; Francesco Paolo Cantatore
Journal:  Clin Dev Immunol       Date:  2013-06-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.